ADD MEETING LINK:

OBJECTIVES: Upon completion of this activity, the participant should be able to:
1. Identify the importance of recognizing and treating insulin resistance in treatment-resistant bipolar depression.
2. Review the results of a 26-week proof-of-concept study that utilized metformin as an insulin sensitizer to convert a substantial percentage of treatment-resistant bipolar depression patients to experience improved clinical outcomes.
3. Review potential mechanisms underlying treatment-resistant bipolar depression associated with insulin resistance.
4. Discuss the measurement of insulin resistance and the clinical predictive models to predict IR reversal with metformin inpatients with treatment-resistant depression.

FACULTY DISCLOSURE: Dr. Chengappa, Dr. Calkin and Dr. Gannon have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE: The planners have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Melissa.Campbell@BSWHealth.org